EP. 1: An Overview of the Cervical Cancer Landscape: Key Advances and Recent Approvals
Robert L. Coleman, MD, FACOG, FACS, reviews the treatment landscape of cervical cancer and identifies recent approvals that have improved patient care.
EP. 2: Balstilimab in Advanced Cervical Cancer: Rationale and Key Efficacy Outcomes
Focusing on novel immune checkpoint inhibitors, Robert L. Coleman, MD, FACOG, FACS, breaks down preclinical and clinical data that support use of balstilimab in patients with advanced cervical cancer.
EP. 3: Combining Balstilimab With Zalifrelimab in Patients With Advanced Cervical Cancer
Expert insight on the combination of balstilimab, a PD-1 inhibitor, and zalifrelimab, a CTLA-4 inhibitor, in patients with recurrent or metastatic cervical cancer.
EP. 4: Advanced Cervical Cancer: Toxicity Management With Balstilimab + Zalifrelimab
Robert L. Coleman, MD, FACOG, FACS, shares practical advice on managing toxicities while treating cervical cancer with the combination of balstilimab and zalifrelimab.
EP. 5: Practical Advice on Sequencing Therapies and the Care of Cervical Cancer Patients
Closing out his discussion on the treatment of cervical cancer, Robert L. Coleman, MD, FACOG, FACS, provides thoughts on the optimal sequencing of therapy and importance of clinical trials.
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer
Frontline Ribociclib Plus Endocrine Therapy Provides PFS Benefit in Pre/Perimenopausal HR+/HER2- Advanced Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.